MAGEC2 and hepatocellular carcinoma: Immunohistochemical studies revealed that HCA587 protein (34–37%) was more frequently detected than NY-ESO-1 (7.3–23.3%) and MAGE-A3 (7%) in hepatocellular carcinoma patients [19], [22], [23], [24], [25].